Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors
- 15 November 2010
- journal article
- Published by Informa UK Limited in Cancer Biology & Therapy
- Vol. 10 (10), 983-993
- https://doi.org/10.4161/cbt.10.10.13251
Abstract
Background: Single-dose infusion of the agonistic anti-CD40 monoclonal antibody (mAb) CP-870,893 accomplishes immune activation and clinical responses in patients with advanced cancers, but repeat dosing of this agent has not been reported. Patients and methods: Patients with advanced solid tumor malignancies received weekly intravenous infusions of CP-870,893 in four dose level cohorts. Safety and immune pharmacodynamics were assessed. Results: Twenty-seven patients were enrolled. The most common adverse event was transient, infusion-related cytokine release syndrome (CRS). Dose-limiting toxicities included grade 3 CRS and grade 3 urticaria; the maximum tolerated dose (MTD) was estimated to be 0.2 mg/kg. Seven patients (26%) had stable disease as the best clinical response; no partial or complete responses were observed. At the MTD, patient B lymphocytes exhibited persistently increased expression of costimulatory and adhesion molecules without resetting to baseline between doses. In 4 of 8 patients (50%) evaluated at the MTD, there were marked declines in total CD3+ T lymphocytes, as well as CD4+ and CD8+ subsets. Conclusions: Weekly infusions of the agonist CD40 antibody CP-870,893 were well-tolerated, but there was little clinical activity in advanced cancer patients. Correlative studies demonstrate chronic B cell activation and in some patients, T cell depletion. Longer dosing intervals may be desirable for optimal immune pharmacodynamics.Keywords
This publication has 27 references indexed in Scilit:
- Effector and regulatory B cells: modulators of CD4+ T cell immunityNature Reviews Immunology, 2010
- Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulationJournal of Translational Medicine, 2009
- Cytotoxic T-Lymphocyte–Associated Antigen-4Clinical Cancer Research, 2007
- An Agonist Antibody Specific for CD40 Induces Dendritic Cell Maturation and Promotes Autologous Anti‐tumour T‐cell Responses in an In vitro Mixed Autologous Tumour Cell/Lymph Node Cell ModelScandinavian Journal of Immunology, 2007
- Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal AntibodyJournal of Clinical Oncology, 2007
- Prospect of Targeting the CD40 Pathway for Cancer TherapyClinical Cancer Research, 2007
- Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk NeuroblastomaJournal of Clinical Oncology, 2006
- RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapyBlood, 2004
- CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.JCI Insight, 1997
- The CD40 Antigen and its LigandAnnual Review of Immunology, 1994